C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma

Abstract

ObjectivesMany studies have examined histopathological factors and various prognostic scores related to inflammation to predict outcomes. Here, we examined the prognostic value of the C-reactive protein/albumin (CRP/alb) ratio in oral squamous cell carcinoma (OSCC).Materials and MethodsThis retrospective study included 40 patients with OSCC. Using univariate and multivariate analyses, we focused on the correlation of the CRP/alb ratio with clinicopathological characteristics and with overall survival. We then compared five inflammation-based prognostic scores, CRP/alb ratio, modified Glasgow Prognostic Score (mGPS), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and prognostic nutritional index (PNI), based on receiver operating characteristic (ROC) curves.ResultsThe optimal cut-off value for the CRP/alb ratio was 0.085. The group with a high CRP/alb ratio had a high TNM clinical stage (P=0.002) and larger primary tumors (P=0.029), with statistically significant differences in lymph node metastasis and distant metastasis. In addition, when the CRP/alb ratio was high, multivariate analysis showed a lower survival rate (P=0.002; hazard ratio=6.078), and the ROC curve showed more outstanding discriminatory ability regarding overall survival compared to other inflammation-based prognostic scores.ConclusionThe CRP/alb ratio can be an independent prognostic factor when predicting prognosis in OSCC and has good prognostic ability.

The value of preoperative Glasgow Prognostic Score and the C-Reactive Protein to Albumin Ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma

“…In the same year, Xiao-ling Xu et al and Xiao-li Wei et al had explored the prognostic value of CAR in operable and non-selected ESCC patients, respectively and the area under the curve (AUC) values of the CAR was proved higher than the other inflammation-based prognostic scores at 12 months, 24 months, and 36 months 20 , 21 , which was consistent with our analysis 21 . In addition, similar to the above mentioned reports, the novel but promising CAR has been identified as an independent prognostic factor for OS in our study by multivariate analysis as well 29 , 30 . The summary of these relevant studies are showed in supplementary table (Table S2 ).…”

Clinicopathologic and prognostic significance of C-reactive protein/albumin ratio in patients with solid tumors: an updated systemic review and meta-analysis

“…A total of 10203 patients diagnosed with various cancers, including laryngeal squamous cell carcinoma (LSCC) [ 22 ], ovarian cancer (OC) [ 23 ], renal cell carcinoma (RCC) [ 24 ], non-small cell lung cancer (NSCLC) [ 25 ], pancreatic cancer (PC) [ 26 – 29 ], colorectal cancer (CRC) [ 30 – 33 ], nasopharyngeal cancer (NPC) [ 21 , 34 – 36 ], gastric cancer (GC) [ 37 , 42 ], oral squamous cell carcinoma (OSCC) [ 38 ], hepatocellular carcinoma (HCC) [ 39 , 43 ], esophageal squamous cell carcinoma (ESCC) [ 40 , 41 ], small cell lung cancer (SCLC) [ 44 ], were included. These studies originated from China [ 21 – 24 , 27 , 28 , 33 – 36 , 39 – 42 , 44 ], Japan [ 26 , 30 – 32 , 37 , 43 ], and Korea [ 25 , 29 , 38 ], respectively. Twenty-three articles reported the outcomes of overall survival (OS) [ 21 – 31 , 33 – 44 ], and 6 studies presented disease free survival (DFS) as survival endpoint [ 22 , 24 , 26 , 32 , 34 , 37 ].…”

“…Twenty-three articles reported the outcomes of overall survival (OS) [ 21 – 31 , 33 – 44 ], and 6 studies presented disease free survival (DFS) as survival endpoint [ 22 , 24 , 26 , 32 , 34 , 37 ]. Seventeen studies included cancer patients with all disease stages (Stage I–IV or limited-extensive stage) [ 22 – 26 , 28 – 31 , 34 – 36 , 38 , 39 , 41 , 43 , 44 ], three studies recruited patients with Stage I–III [ 37 , 40 , 42 ], and four studies reported advanced stages (III, IV, or III-IV) [ 21 , 27 , 32 , 33 ]. The primary treatments were extremely various among these 24 included studies, including surgery [ 22 – 24 , 26 , 31 , 37 – 43 ], chemotherapy (CT) [ 21 , 25 , 27 , 29 , 30 , 32 , 33 , 44 ], and concurrent chemoradiotherapy (CCRT) [ 34 – 36 ].…”

Neutrophil‐to‐lymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta‐analysis

“…The PRISMA flow chart of the systematic review can be found in Figure . An initial search done using the search strategy (Supporting Materials) obtained an initial 900 results.…”